Opendata, web and dolomites

FORMBECC

LaminarPace System: a breakthrough technology for dry-formulation of sensitive pharmaceuticals at room temperature enhancing their stability beyond the cold chain

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

Project "FORMBECC" data sheet

The following table provides information about the project.

Coordinator
ZICCUM AB 

Organization address
address: HALSOVAGEN 7
city: HUDDINGE
postcode: 141 57
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Sweden [SE]
 Project website http://ziccum.com/ziccum-awarded-0-5-msek-from-horizon-2020-eus-biggest-research-and-innovation-program/
 Total cost 71˙429 €
 EC max contribution 50˙000 € (70%)
 Programme 1. H2020-EU.3. (PRIORITY 'Societal challenges)
2. H2020-EU.2.3. (INDUSTRIAL LEADERSHIP - Innovation In SMEs)
3. H2020-EU.2.1. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies)
 Code Call H2020-SMEInst-2018-2020-1
 Funding Scheme SME-1
 Starting year 2018
 Duration (year-month-day) from 2018-08-01   to  2019-01-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    ZICCUM AB SE (HUDDINGE) coordinator 50˙000.00

Map

 Project objective

Formulation of sensitive drugs in a stable manner poses problems with currently applied technologies: the substances need to be either heated up to 80 °C or frozen to -80 °C. Many valuable biological pharmaceuticals need to be kept and transported in a liquid phase at fixed temperatures, which renders them impractical and costly. The global healthcare community, with the World Health Organisation in the lead, is looking for options to step out of the cold chain and provide more accessible medication to all communities. In the LaminarPace project, Ziccum AB is developing a gentle, room temperature spray-drying technology for the application in the pharmaceutical industry. The system is operational on a laboratory scale and pilot-tested now. It could successfully lead to the development of new biologics: vaccines, drugs and therapies. An industrial-scale system based on the same principles of operation will be developed and commercialised. The objective is to set the large system into BioTech production lines. LaminarPace process is fully controllable according to Good Manufacturing Practice and produces carefully-engineered, stable and easily-absorbed formulations.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "FORMBECC" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "FORMBECC" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.;H2020-EU.2.3.;H2020-EU.2.1.)

MEDIVAC (2019)

Machine learning software to design personalized neoantigen vaccines tailored to specific vaccine delivery systems

Read More  

RDNA (2019)

Empowering New Venture Growth - RDNA

Read More  

SIMCARE (2019)

SImulation-assisted Minimally invasive CAncer tREatment using the gosmart environment

Read More